ライフサイエンスコーパス: refractory disease

1 were treatment naive and 92 had relapsed or refractory disease).

2 were treatment-naive and 27 had relapsed or refractory disease).

3 ble at first relapse or first designation of refractory disease.

4 acute myeloid leukemia (AML) is chemotherapy refractory disease.

5 seases could be considered for patients with refractory disease.

6 men is typically recommended for relapsed or refractory disease.

7 disease, and five patients (9%) had primary refractory disease.

8 every 21 days (R-CHOP21) relapse or develop refractory disease.

9 fficacy in murine HLH models and humans with refractory disease.

10 targeted drugs in patients with radioiodine-refractory disease.

11 rapies and induce remission in patients with refractory disease.

12 (>/=1 lymph nodes >/=5 cm), and 37 (58%) had refractory disease.

13 oma by prevention or successful treatment of refractory disease.

14 of tandem autologous transplant in breaking refractory disease.

15 explore its effects on transition to hormone-refractory disease.

16 zole) have been demonstrated to be useful in refractory disease.

17 being more heavily pretreated and with more refractory disease.

18 improved tumour control and reduced rates of refractory disease.

19 dditional therapeutic choices to consider in refractory disease.

20 ed clonal expansion in patients with steroid-refractory disease.

21 ology will aid in treatment of a complex and refractory disease.

22 , particularly for patients with advanced or refractory disease.

23 may identify additional treatment options in refractory disease.

24 hese patients was 2 (range, 0-5) and 43% had refractory disease.

25 ole in the treatment of cancer patients with refractory disease.

26 herapy has been studied to address treatment-refractory disease.

27 promising therapeutic option in this highly refractory disease.

28 d in all CTCL stages as well as in treatment-refractory disease.

29 r patients with advanced stage and treatment-refractory disease.

30 al settings, frequently resulting in chronic refractory disease.

31 ensitive disease, and 18 were allografted in refractory disease.

32 ate cancer, in particular those with hormone-refractory disease.

33 develop the new variants present in hormone-refractory disease.

34 (H), and of 25% in patients with fludarabine-refractory disease.

35 r later therapy or in patients with platinum-refractory disease.

36 calized prostate cancer remains an extremely refractory disease.

37 cancer in both hormone-sensitive and hormone-refractory disease.

38 ovide outstanding local-regional control for refractory disease.

39 be effective therapeutic agents for steroid-refractory disease.

40 ed to novel treatment strategies for steroid-refractory disease.

41 peutic options for patients with relapsed or refractory disease.

42 Overall, 10% had refractory disease.

43 mor initiation to the development of therapy refractory disease.

44 nificant challenges remain for recurrent and refractory disease.

45 of greater than 60% in patients with steroid-refractory disease.

46 reclinical models and patients with relapsed refractory disease.

47 ion has been proposed as salvage therapy for refractory disease.

48 and warrants investigation in patients with refractory disease.

49 of initial therapy and in the management of refractory disease.

50 ents with NSCLC, including 142 patients with refractory disease.

51 relieve the symptoms of advanced, medically refractory disease.

52 e chemotherapy and patients with relapsed or refractory disease.

53 ion method to identify cured versus fatal or refractory disease.

54 chemotherapy should be reserved for hormone-refractory disease.

55 y because of the development of progressive, refractory disease.

56 apy and may serve as a diagnostic marker for refractory disease.

57 activation of androgen signaling in hormone refractory disease.

58 outcomes of patients with poor-risk primary refractory disease.

59 f MDR prior to selection and/or induction of refractory disease.

60 , few have demonstrated activity in platinum-refractory disease.

61 trated to be efficacious in the treatment of refractory disease.

62 antiangiogenic properties, in patients with refractory disease.

63 tastases (n = 62) from patients with hormone-refractory disease.

64 92 with Crohn's disease required surgery for refractory disease.

65 Cyclosporine A was effective for refractory disease.

66 -refractory disease, and 95% had daratumumab-refractory disease.

67 e malignancy without effective therapies for refractory disease.

68 PV- HNSCC, a subset still develops recurrent/refractory disease.

69 still require proctocolectomy for medically refractory disease.

70 ents with heavily pretreated relapsed and/or refractory disease.

71 with poor outcomes in patients with relapsed/refractory disease.

72 ntial fraction of patients with chemotherapy refractory disease.

73 patients are more likely to relapse or have refractory disease.

74 ma, and outcomes remain poor for relapsed or refractory disease.

75 ilta-cel's clinical efficacy in lenalidomide-refractory disease.

76 ineligible and for patients with relapsed or refractory disease.

77 inal sites were highly predictive of primary refractory disease.

78 increased asthma severity and glucocorticoid-refractory disease.

79 can salvage >80% of patients having relapsed/refractory disease.

80 volume (TMTV) could detect early relapse or refractory disease.

81 to identify imaging findings associated with refractory disease.

82 in particular effective agents to treat TKI-refractory disease.

83 b-based option is reasonable for relapsed or refractory disease.

84 of ibrutinib in a population with rituximab-refractory disease.

85 y in asthmatics with neutrophilia and severe refractory disease.

86 ete remissions in patients with chemotherapy refractory disease.

87 particularly when colectomy is performed for refractory disease.

88 he time of initiation of salvage therapy for refractory disease.

89 ies, virtually all develop progressive, drug-refractory disease.

90 eatment step 4 to 5 asthma, and 13 of 17 had refractory disease.

91 roduced responses in patients with relapsed, refractory disease.

92 activity may be effective in combating this refractory disease.

93 ons for patients with macrolide-resistant or refractory disease.

94 markers in both treatment-naive and relapsed/refractory disease.

95 biomarker for new therapeutic approaches to refractory disease.

96 viously untreated CLL and 16 had relapsed or refractory disease.

97 role in patients with high-risk or relapsed/refractory disease.

98 n favor of tumor cell survival and treatment-refractory disease.

99 on may reflect CMB accrual over time or more refractory disease.

100 fication was common in primary resistant and refractory disease.

101 uding with cells from patients with relapsed/refractory disease.

102 andard of care for patients with relapsed or refractory disease.

103 ll-tolerated in older patients with relapsed/refractory disease.

104 options are needed particularly for severe, refractory disease.

105 oved responses at first line and in relapsed/refractory disease.

106 with emphasis on juvenile disease and adult refractory diseases.

107 xploration of nelarabine against fludarabine-refractory diseases.

108 conferring long-term remission for otherwise refractory diseases.

109 ar target organs, are promising for treating refractory diseases.

110 advantages and great potential for treating refractory diseases.

111 1 to 16 years of age (relapsed disease, 19; refractory disease, 10) received gemtuzumab ozogamicin r

112 Group performance status of 2, 33 (54%) had refractory disease, 13 (21%) relapsed within 1 year of f

113 th heavily pretreated neuroblastoma (12 with refractory disease, 14 with relapsed disease, and 1 with

114 18%; P = .05) and in those who had platinum-refractory disease (25% v 15%; P = .14).

115 ziv-aflibercept in patients who had platinum-refractory disease (27% v 10%; P = .02) but not in patie

116 ] age, 63 [36-86] years; 17.9% with platinum-refractory disease; 53.6% with >=3 prior therapies) were

117 treated, 119 patients (76%) had triple-class-refractory disease, 55 (35%) had extramedullary disease,

118 Among patients with relapsed or refractory disease, 56 underwent hematopoietic stem cell

119 an 5 [range 2-14] prior regimens), treatment-refractory disease (70%), unmutated IGHV (91%), and del1

120 tinum-resistant disease, and 13 had platinum-refractory disease (according to platinum-free interval)

121 of 53 (43%, 30-58) patients with relapsed or refractory disease achieved an overall response.

122 Evidence of such blasts at diagnosis heralds refractory disease across independent datasets and is as

123 PR) after first transplant in eight, and (4) refractory disease after first transplant in two.

124 ly a subset of patients develop recurrent or refractory disease after first-line treatment.

125 were treatment-naive and 27 had relapsed or refractory disease after previous hypomethylating agent

126 ing agent treatment-naive or had relapsed or refractory disease after previous hypomethylating agent

127 All patients had relapsed or refractory disease after previous treatment with a BCR s

128 e large B-cell lymphoma, who relapsed or had refractory disease after previous treatment with one to

129 e likely to experience disease recurrence or refractory disease after rituximab plus cyclophosphamide

130 second transplant) who achieved a PR or had refractory disease after the first transplant.

131 er, in metastases from patients with hormone-refractory disease, amplification of the androgen recept

132 Patients were required to have relapsed/refractory disease, an absolute neutrophil greater than

133 27 patients were diagnosed with relapsed or refractory disease and 12 died.

134 90%), including 2 patients with blinatumomab-refractory disease and 15 who had undergone stem-cell tr

135 th activity in CLL patients with fludarabine-refractory disease and 17p deletion.

136 Thirty-eight percent had refractory disease and 29% a Karnofsky performance score

137 pression is strongly associated with hormone-refractory disease and advanced tumor stage in prostate

138 oma (HL) include difficult-to-treat relapsed/refractory disease and considerable long-term toxicities

139 ents with adverse prognostic factors such as refractory disease and increased beta2-microglobulin, pa

140 chronic disease ranging from mild to severe refractory disease and is classified into various clinic

141 Patients with refractory disease and LG-NHL did not benefit from a sec

142 A small proportion have refractory disease and may benefit from an alternate tre

143 ic B-ALL patients with multiply relapsed and refractory disease and normal karyotype or low risk cyto

144 ons exist; however, many patients experience refractory disease and novel treatments are needed.

145 However, refractory disease and the emergence of antigen-loss tum

146 patient underwent to colectomy for a medical refractory disease and the histological examination of t

147 use large B-cell lymphoma (DLBCL), including refractory disease and the second-line age-adjusted inte

148 CR, 2 after salvage therapy for relapsed or refractory disease, and 1 after alternative treatment fo

149 in the efficacy population (N = 52), 58% had refractory disease, and 42% had relapsed disease.

150 otal of 66% of the patients had triple-class-refractory disease, and 95% had daratumumab-refractory d

151 ear-CR, including several with anthracycline-refractory disease, and another 8 having partial respons

152 loss of NIS expression, function, or both in refractory disease, and discuss preclinical and clinical

153 t in the modern era, age >=45 years, primary refractory disease, and lack of complete remission pre-A

154 f cases of T-ALL, including >85% of relapsed/refractory disease, and only on a small fraction (<5%) o

155 5 years or older, 181 (67%) had chemotherapy-refractory disease, and seven (3%) had secondary CNS inv

156 oma, but prevalence increases in late-stage, refractory disease, and the mutations are associated wit

157 reatment options for patients with rituximab-refractory disease are an important clinical need.

158 -Hodgkin lymphoma (NHL), relapses or primary refractory disease are commonly observed and associated

159 endence and effective treatments for hormone-refractory disease are described.

160 rophylaxis, initial therapy, and therapy for refractory disease are discussed.

161 Patients with relapsed/refractory disease are generally treated with immune-mod

162 Effective chemotherapy regimens for refractory disease are scarce, accounting for no improve

163 erapy and in multiagent regimens in relapsed/refractory disease as well as frontline settings.

164 f patients with lenalidomide- and bortezomib-refractory disease as well as in patients with high-risk

165 2.23; 95% CI, 1.02-4.87), indicative of ACV-refractory disease, as independent risk factors for ACV(

166 Relapsed/refractory disease at CBT, recipient HLA-C2/C2 genotype,

167 Relapsed/refractory disease at study entry, TP53 aberration, adva

168 sed the number of patients with lenalidomide-refractory disease at the time of the first relapse.

169 t within the previous 3 months, did not have refractory disease, autoimmune haemolytic anaemia requir

170 fferentiated thyroid cancer have radioiodine-refractory disease, based on decreased expression of the

171 lantation, high lactate dehydrogenase (LDH), refractory disease, bone marrow involvement, low perform

172 ty was observed in patients with fludarabine-refractory disease, bulky adenopathy, and del(17p) CLL.

173 The RICs offer significant potency, even in refractory disease, but their complexity may limit their

174 innovations for countering heterogeneous and refractory disease by virtue of their ability to bind tw

175 Recurrent or refractory disease can be effectively treated or cured w

176 In a subset of patients with relapsed or refractory disease, CCS1477 monotherapy induces differen

177 Neuropathic pain is a refractory disease characterized by maladaptive changes

178 ression from clinically localized to hormone refractory disease, coinciding with an increase in Akt a

179 ment practices vary widely and management of refractory disease continues to be challenging.

180 e prognosis of patients with relapsed and/or refractory disease continues to be poor; thus, a continu

181 Characteristics associated with refractory disease course and blindness were evaluated u

182 Seven (47%) of 15 patients with rituximab-refractory disease demonstrated reduction in their tumor

183 , or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior

184 Refractory disease developed in no patients in the capla

185 t outcome, 65% of patients with relapsed and refractory disease do not respond.

186 1) ocular disorders, may pose a risk for ACV-refractory disease due to ACV resistance.

187 long-term ACV prophylaxis predisposes to ACV-refractory disease due to the emergence of corneal ACV(R

188 However, patients with "double-refractory" disease due to the acquired resistance to bo

189 term follow-up of patients with relapsed and refractory disease, especially in the presence of TP53 a

190 s and the need for effective drugs in highly refractory disease, etirinotecan pegol may warrant furth

191 a expected to express CD20, with relapsed or refractory disease following at least one previous syste

192 se (>1.5 cm) by CT scan, and had relapsed or refractory disease following one or more previous lines

193 l-cell lung cancer, all of whom had platinum-refractory disease, had a partial response or prolonged

194 is efficacious in patients with relapsed or refractory disease harboring MYD88 L265P mutation.

195 Patients with refractory disease, history of bowel obstruction, or > t

196 rter with mitumprotimut-T/GM-CSF in relapsed/refractory disease (HR = 2.265; P = .004).

197 Nineteen (76%) had refractory disease immediately before enrollment.

198 ough benefit was first shown in relapsed and refractory disease, improved overall response, duration

199 eting CD19 induced lasting remission of this refractory disease in a number of patients.

200 (MM); however, 65% of patients with relapsed refractory disease in a phase II study do not respond to

201 st indicators of aggressive and chemotherapy-refractory disease in children with neuroblastoma, the m

202 Gorlin syndrome and nonmetastatic BCCs, but refractory disease in distantly metastatic tumors has no

203 tes with the progression to advanced hormone refractory disease in patient samples.

204 xist, which might contribute to recurrent or refractory disease in some patients.

205 cases include those individuals with hormone-refractory disease in the absence of clinical metastases

206 possibly prevent the emergence of bortezomib-refractory disease in the clinic.

207 patients, it is of paramount importance for refractory disease in view of the longer duration of pan

208 ression in samples from patient with hormone refractory disease in which AR expression levels corresp

209 reased rapidity of periodontal bone loss and refractory disease incidence in smokers.

210 for the development of AR-dependent hormone-refractory disease, including changes in expression of A

211 depletion could be useful for patients with refractory disease, including lupus nephritis, and antib

212 in seven (70%) of 10 patients with pazopanib-refractory disease, including one patients with RCC with

213 patients, 636 were included on the basis of refractory disease inclusion criteria.

214 Progression of prostate cancer to androgen-refractory disease is correlated with increased expressi

215 le in the treatment of patients with primary refractory disease is not well defined.

216 Progression to hormone refractory disease is often correlated with overexpressi

217 A promising strategy for patients with refractory disease is targeting B cells with CD19-target

218 notherapy, but with relapses with treatment, refractory disease is the most common outcome, especiall

219 Although hormone-refractory disease is unresponsive to androgen-deprivati

220 mized trial has been conducted for recurrent/refractory disease, leaving many questions unanswered ab

221 emain the mainstay of therapy; patients with refractory disease may respond to other immunomodulating

222 tional Institutes of Health score "severe"), refractory disease (median treatments = 4).

223 received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines)

224 DCT as third-line or later therapy, platinum-refractory disease, mediastinal primary tumor site, nons

225 of adult and juvenile myositis patients with refractory disease met the DOI.

226 t, clinicians treating patients with hormone-refractory disease must weigh the benefits of earlier ch

227 outcomes for some patients with relapsed and refractory disease, not all patients have access to thes

228 Food and Drug Administration for relapsed or refractory disease of B-cell lineage.

229 Patients with PTCL with primary refractory disease or early relapse have extremely poor

230 chemotherapy group (hazard ratio for primary refractory disease or first occurrence of progression, r

231 In patients with primary refractory disease or in those with multiple relapses, h

232 dies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL).

233 ment with ibrutinib or other BTK inhibitors, refractory disease or relapse within 24 months with a pr

234 Tumors of Hematopoietic and Lymphoid Tissue; refractory disease or relapsed after autologous stem-cel

235 patients can require colectomy for medically refractory disease or to treat colonic neoplasia.

236 a were aged 18 years of age or older and had refractory disease or were in first relapse after one or

237 s aged 18 years or older who had relapsed or refractory disease or were ineligible for standard treat

238 eal ACV(R) isolate was a risk factor for ACV-refractory disease (OR 2.28; 95% CI, 1.06-4.89).

239 ly relapse after initial chemoimmunotherapy, refractory disease, or histologic transformation (tFL) h

240 Prior PARPi, platinum-refractory disease, or progression on more than two chem

241 ith poor prognostic features, with primarily refractory disease, or with relapsed disease following c

242 lymph node metastasis (P = 0.0002), hormone-refractory disease (P < 0.0001), presence of ERG gene fu

243 ysis were baseline MTV (bMTV) (P < .001) and refractory disease (P = .003).

244 esonide are helpful in patients with steroid-refractory disease, particularly in those with gastroint

245 For refractory disease, patients were randomized between rab

246 Patients were stratified by relapsed versus refractory disease, presence or absence of del(17p) or T

247 ollowed by relapse (adaptive resistance), or refractory disease (primary resistance).

248 Of 6 patients with refractory disease prior to treatment, 2 had complete re

249 Responses were seen in patients with prior refractory disease, prior ASCT, and prior alloSCT; howev

250 apse or progression, or first designation of refractory disease, provided organ function requirements

251 evious lines of therapy and had triple-class refractory disease (refractory to immunomodulatory drugs

252 ia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity.

253 atment-related toxicities and a high rate of refractory disease/relapse even after allogeneic hematop

254 incorporating these in patients with double-refractory disease, remaining cognizant of the variabili

255 hich treatment of patients with relapsed and refractory disease remains a challenge.

256 d-line treatments for advanced relapsing and refractory disease remains a priority.

257 the treatment of patients with relapsed and refractory disease remains challenging.

258 ds as a first-line option, the treatment for refractory disease remains contentious and lacks a stand

259 ue sarcomas, however, prognosis for advanced refractory disease remains poor.

260 but significant part of the cases present a refractory disease representing unmet medical needs.

261 Hormone refractory disease represents a late-stage and generally

262 For patients with steroid-refractory disease, response to second-line treatment is

263 s, targets, and opportunities to resensitize refractory disease.See related commentary by Canman, p.

264 In relapsed or refractory disease, selected compounds appear to have ac

265 and durability of remission in the relapsed/refractory disease setting.

266 Advanced and platinum-refractory disease states continue to be challenging ent

267 rom baseline PET scans predicted relapsed or refractory disease status in a cohort of 251 patients wi

268 treatment of Hodgkin Lymphoma, patients with refractory disease still have a poor prognosis.

269 linical course and inevitable development of refractory disease, stressing the need to develop altern

270 of patients with chemotherapy- and rituximab-refractory disease, suggesting that bendamustine may be

271 ic drug in patients with mainly relapsed and refractory disease suggests that haematological response

272 The high response rate in refractory disease suggests that this agent may be usefu

273 Temporomandibular joint (TMJ) ankylosis is a refractory disease that is difficult to predictably trea

274 Relapsed or refractory disease that is resistant to ATRA is a clinic

275 in patients with early-relapsing or primary refractory disease, the ORR was 55% and CR 30%.

276 Patients with radioiodine-refractory disease, therefore, are not amenable to (131)

277 the critical roles that GAS6 and AXL play in refractory disease, this signaling axis represents an at

278 improvement in OS was noted in patients with refractory disease treated with amrubicin.

279 We report 4 patients with refractory disease treated with rituximab who had clinic

280 r less were requirements for the relapsed or refractory disease treatment cohort, without any limits

281 Ten patients had primary refractory disease, two were in first remission, and two

282 e chemoimmunotherapy, patients with relapsed/refractory disease typically have poor outcomes.

283 with unresponsive, high-risk disease because refractory disease typically retains radiation sensitivi

284 clax-gilteritinib off label after developing refractory disease under venetoclax-azacitidine.

285 erall survival for patients with relapsed or refractory disease, underscoring the need for close moni

286 ne treatment for ITP; however, patients with refractory disease usually require splenectomy.

287 Outcome for patients who had recurrent or refractory disease was poor: only four (22%) patients ac

288 nd among triple-negative breast cancer, more refractory disease was seen among Black patients compare

289 64 patients with newly diagnosed or relapsed/refractory disease, we demonstrate the correlation betwe

290 ho did not proceed to transplantation due to refractory disease were considered transplantation failu

291 radius and identifying trials for recurrent/refractory disease were documented as challenges for pat

292 ent or vincristine/doxorubicin/dexamethasone-refractory disease were eligible for the phase II multi-

293 augICE for relapsed/refractory HL, bMTV and refractory disease were independent prognostic factors f

294 ortive care, up to 40% of patients will have refractory disease, which has a poorly understood biolog

295 a from patients with metastatic or treatment-refractory disease who consented to a clinical protocol

296 with either rituximab-sensitive or rituximab-refractory disease who had at least a partial response.

297 the treatment of patients with relapsed and refractory disease who have received one previous line o

298 atic cholangiocarcinoma (ICC) is a treatment-refractory disease with a dismal outcome.

299 Patients and Methods Patients with RAI-refractory disease with Response Evaluation Criteria in

300 s who are appropriately shown to have iodine-refractory disease, with 1 drug approved by the Food and